Cite
HARVARD Citation
Jabbour, E. et al. (2017). Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 123 (4), pp. 629-637. [Online].